Halozyme Therapeutics, Inc. (HALO)

業務介紹

翻譯結果如下:

哈羅賽姆生物科技公司是一家生物製藥技術平台公司,在美國、瑞士、愛爾蘭、比利時、日本和國際上運營。該公司的產品基於ENHANZE藥物遞送技術,這是一種專利的重組人類透明質酸酶(rHuPH20),可以實現注射生物製劑(如單克隆抗體和其他治療分子)以及小分子和液體的皮下給藥。其旗艦產品是Hylenex重組,這是一種rHuPH20的配方,可以促進皮下液體給藥,實現水合作用,增強其他注射藥物在皮下的擴散和吸收,並改善放射不透明劑的再吸收。該公司還開發了Perjeta、RITUXAN HYCELA和MabThera SC用於治療非霍奇金淋巴瘤和慢性淋巴細胞白血病(CLL)、RITUXAN SC用於CLL患者,以及HYQVIA用於治療免疫缺陷性疾病。此外,該公司正在開發Tecentriq用於非小細胞肺癌、OCREVUS用於多發性硬化症、DARZALEX用於治療淀粉樣變性、隱匿性骨髓瘤和多發性骨髓瘤患者、nivolumab用於治療實體瘤、ARGX-113(一種人新生兒Fc受體)和ARGX-117(用於治療自身免疫性疾病)以及BMS-986179(一種抗CD-73抗體)。該公司與羅氏、Baxalta、輝瑞、強生生物技術、AbbVie、礼利公司、Bristol-Myers Squibb、Alexion Pharma Holding、ARGENX BVBA、Horizon Therapeutics、美國國立過敏和傳染病研究所、南非愛滋病研究中心和ViiV Healthcare Limited等公司有合作關係,用於開發治療和預防HIV的小分子和大分子靶標。哈羅賽姆生物科技公司成立於1998年,總部位於加利福尼亞州聖地亞哥。



Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

公司網址

https://www.halozyme.com